RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RXST
The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or “the Company”) (
NASDAQ: RXST) for violations of the securities laws.
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or “the Company”) (
NASDAQ: RXST) for violations of the securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXSTNEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of (“RxSight” or the “Company”) (
NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (
NASDAQ: RXST) for potential violations of the federal securities laws.
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (
NASDAQ: RXST) investors concerning the Company’s possible violations of the federal securities laws.
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (
NASDAQ: RXST) investors concerning the Company’s possible violations of federal securities laws.
RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces Investigation into RxSight, Inc. (RXST) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz continues its investigation of RxSight, Inc. (“RxSight” or the “Company”) (
NASDAQ: RXST) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (
NASDAQ: RXST) investors concerning the Company’s possible violations of the federal securities laws.
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (
NASDAQ: RXST) investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of RxSight, Inc. (“RxSight” or the “Company”) (
NASDAQ: RXST) on behalf of investors concerning the Company’s possible violations of federal securities laws.
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 GuidanceALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time.
RxSight, Inc. Reports First Quarter 2025 Financial ResultsALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025.
RxSight, Inc. to Present at the Bank of America Healthcare ConferenceALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas.
RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 GuidanceALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare ConferenceALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference.
RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 GuidanceALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024.
RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 GuidanceALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
RxSight, Inc. to Present at the J.P. Morgan Healthcare ConferenceALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
RxSight, Inc. Reports Third Quarter 2024 Financial ResultsALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (
NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024.
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
